The Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Improving Morbidity and Mortality of Heart Failure: A Systematic Review

Cardiovascular disease (CVD) is the leading cause of mortality in patients with type 2 diabetes mellitus (DM) worldwide. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) were initially developed for treating patients with type 2 DM. The four major drugs developed are canagliflozin, dapagliflozin,...

Descripción completa

Detalles Bibliográficos
Autores principales: Thiagaraj, Suvedha, Shukla, Twisha S, Gutlapalli, Sai Dheeraj, Farhat, Hadi, Irfan, Huma, Muthiah, Kanmani, Pallipamu, Namratha, Taheri, Sogand, Khan, Safeera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016728/
https://www.ncbi.nlm.nih.gov/pubmed/36938250
http://dx.doi.org/10.7759/cureus.34942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016728/
https://www.ncbi.nlm.nih.gov/pubmed/36938250
http://dx.doi.org/10.7759/cureus.34942

Ejemplares similares